Insights & news

World Health Organisation Approves Resolution on Price Transparency

  • 31/05/2019
  • Articles

On 28 May 2019, the final plenary of the World Health Assembly (“WHA”), the decision-making body of the World Health Organisation (“WHO”), approved a resolution entitled “Improving the transparency of markets for medicines, vaccines and other health products”. The resolution, originally proposed by Italy, was adopted on the last day of the 72nd WHA, which took place in Geneva from 20 to 28 May 2019. According to WHO officials, this “landmark measure” could have lasting impact on prices in markets for urgently-needed health products, ranging from treatments for cancer and hepatitis, to insulin.

The goal of the resolution is to improve transparency in pharmaceutical markets, from the cost of research and development, including clinical trials, to the prices negotiated by countries and the amount of public funding given. More specifically, the resolution calls on states to “take appropriate measures to publicly share information on the net prices of health products” which it defines as “the amount received by manufacturers after subtraction of all rebates, discounts, and other incentives”. It also asks the WHO’s secretariat to monitor the impact of transparency on access to medicines, including the effect of differential pricing.

Many countries co-sponsored the resolution, including Brazil, Japan, Norway, Spain, Switzerland, Thailand and the United States. Others, however, such as Germany, Hungary and the UK, strongly disagreed with the resolution’s far-reaching implications and disassociated themselves from it on voting day.

In particular, debates took place over the costs relating to research and development. The final language underlines the voluntary nature of the resolution, urging states to “take the necessary steps, as appropriate, to support dissemination of and enhanced availability of and access to aggregated results data and, if already publicly-available or voluntarily-provided, costs from human subject clinical trials regardless of outcomes or whether the results will support an application for marketing approval, while ensuring patient confidentiality”. This version is watered-down from the original text, which did not include the voluntary provision, and instead called on states to provide the cost information as necessary.

The resolution coincides with what would seem to be a general trend towards more price transparency. For example, on 15 May 2019, Beneluxa cited transparency as a “key contributor to achieving sustainability of access to medicines”. Conversely, Poland is reportedly working on legislation that would limit information on negotiations with pharmaceutical companies. Though Poland was part of the consensus to approve the resolution, it initially was against it, since it has been trying to limit making public information on medicine prices.

Pharmaceutical companies and lobby groups disagree about the impact of this resolution on the industry. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) warned that disclosing prices could make it harder for the industry to offer lower prices to poorer countries. The group also raised concerns about how much time was given to the discussions relating to the resolution, a feeling that was shared by the opposing countries, such as Germany. On the other hand, some groups applauded the resolution, seeing it as an essential step to improve universal access to medicines.

The WHA is, as noted, the decision-making body of the WHO and is attended by delegations from all WHO Member States. It focuses on a specific health agenda prepared by the Executive Board. Resolutions, though not legally binding, represent the will of member states and the highest level of commitment. The WHA can also adopt binding decisions, but these need to be presented as a convention or an agreement and require a two-thirds majority.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 04/06/2020
    • Articles

    Europe - Four-Country Inclusive Vaccine Alliance In Quest for Covid-19 Vaccine

    In a letter to Parliament and a press release (see, attachments), the Dutch Minister for Public Health, Wellbeing and Sports, Hugo de Jonge, revealed on 3 June 2020 an initiative of Italy, France, Germany and The Netherlands to work together to secure a Covid-19 vaccine for “the European Union and other countries”.   According to the Minister, the “Inclusive Vaccine Alliance” (IVA) is in talks with several pharmaceutical companies regarding promising ventures and in the process hopes to establish a European manufacturing base for the vaccine. The IVA’s ultimate goal is to create a medicine that is “accessible, available and affordable”.   Other countries will be given the opportunity to join the IVA which is also in contact with the European Commission.

    Read more
    • 03/06/2020
    • Articles

    European Commission Publishes Roadmap Towards Pharmaceutical Strategy for Europe

    The European Commission (the Commission) published on 2 June 2020 its roadmap towards a Pharmaceutical Strategy for Europe (PSE) which it plans to publish in the fourth quarter of 2020 (see, attachment). The roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE. While the Commission will consult a range of stakeholders, it has already announced a public consultation which will run until 7 July 2020.

    Read more
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *